Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 418

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants

Open access
Madhi, Shabir A., Polack, Fernando P., Piedra, Pedro A., Munoz, Flor M., Trenholme, Adrian A., Simões, Eric A.F., Swamy, Geeta K., Agrawal, Sapeckshita, Ahmed, Khatija, August, Allison, Baqui, Abdullah H., Calvert, Anna, Chen, Janice, Cho, Iksung, Cotton, Mark F., Cutland, Clare L., Englund, Janet A., Fix, Amy, Gonik, Bernard, Hammitt, Laura, Heath, Paul T., de Jesus, Joanne N., Jones, Christine E., Khalil, Asma, Kimberlin, David W., Libster, Romina, Llapur, Conrado J., Lucero, Marilla, Pérez Marc, Gonzalo, Marshall, Helen S., Masenya, Masebole S., Martinón-Torres, Federico, Meece, Jennifer K., Nolan, Terry M., Osman, Ayman, Perrett, Kirsten P., Plested, Joyce S., Richmond, Peter C., Snape, Matthew D., Shakib, Julie H., Shinde, Vivek, Stoney, Tanya, Thomas, D. Nigel, Tita, Alan T., Varner, Michael W., Vatish, Manu, Vrbicky, Keith, Wen, Judy, Zaman, Khalequ, Zar, Heather J., Glenn, Gregory M., Fries, Louis F. · 2020 · New England Journal of Medicine

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) is the dominant cause of severe lower respiratory tract infection in infants, with the most severe cases concentrated among younger infants. METHODS: Healthy pregnant women, at 28 weeks 0 days through 36 weeks 0 days of gestation, with an expected delivery date near the start of the RSV season, were randomly assigned in an overall ratio of approximately 2:1 to receive a single intramuscular dose of RSV fusion (F) protein nanoparticle vaccine or placebo. Infants were followed for 180 days to assess outcomes related to lower respiratory tract infection and for 364 days to assess safety. The primary end point was RSV-associated, medically significant lower respiratory tract infection up to 90 days of life, and the primary analysis of vaccine efficacy against the primary end point was performed in the per-protocol population of infants (prespecified criterion for success, lower bound of the 97.52% confidence interval [CI] of ≥30%). RESULTS: A total of 4636 women underwent randomization, and there were 4579 live births. During the first 90 days of life, the percentage of infants with RSV-associated, medically significant lower respiratory tract infection was 1.5% in the vaccine group and 2.4% in the placebo group (vaccine efficacy, 39.4%; 97.52% CI, -1.0 to 63.7; 95% CI, 5.3 to 61.2). The corresponding percentages for RSV-associated lower respiratory tract infection with severe hypoxemia were 0.5% and 1.0% (vaccine efficacy, 48.3%; 95% CI, -8.2 to 75.3), and the percentages for hospitalization for RSV-associated lower respiratory tract infection were 2.1% and 3.7% (vaccine efficacy, 44.4%; 95% CI, 19.6 to 61.5). Local injection-site reactions among the women were more common with vaccine than with placebo (40.7% vs. 9.9%), but the percentages of participants who had other adverse events were similar in the two groups. CONCLUSIONS: RSV F protein nanoparticle vaccination in pregnant women did not meet the prespecified success criterion for efficacy against RSV-associated, medically significant lower respiratory tract infection in infants up to 90 days of life. The suggestion of a possible benefit with respect to other end-point events involving RSV-associated respiratory disease in infants warrants further study. (Funded by Novavax and the Bill and Melinda Gates Foundation; ClinicalTrials.gov NCT02624947.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1908380

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 418

Metadata

Authors
Madhi, S. A., Polack, F. P., Piedra, P. A., Munoz, F. M., Trenholme, A. A., Simões, E. A. F., Swamy, G. K., Agrawal, S., Ahmed, K., August, A., Baqui, A. H., Calvert, A., Chen, J., Cho, I., Cotton, M. F., Cutland, C. L., Englund, J. A., Fix, A., Gonik, B., Hammitt, L., Heath, P. T., de Jesus, J. N., Jones, C. E., Khalil, A., Kimberlin, D. W., Libster, R., Llapur, C. J., Lucero, M., Pérez Marc, G., Marshall, H. S., Masenya, M. S., Martinón-Torres, F., Meece, J. K., Nolan, T. M., Osman, A., Perrett, K. P., Plested, J. S., Richmond, P. C., Snape, M. D., Shakib, J. H., Shinde, V., Stoney, T., Thomas, D. N., Tita, A. T., Varner, M. W., Vatish, M., Vrbicky, K., Wen, J., Zaman, K., Zar, H. J., Glenn, G. M., & Fries, L. F.
Venue
New England Journal of Medicine
Published
2020-07-30
Volume
383
Issue
5
Pages
426-439
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3045880340
Cited by
418
References
10
FWCI
40.86
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. https://app.cochat.ai/papers/10.1056/nejmoa1908380
The paper
Madhi, S. A., Polack, F. P., Piedra, P. A., Munoz, F. M., Trenholme, A. A., Simões, E. A. F., Swamy, G. K., Agrawal, S., Ahmed, K., August, A., Baqui, A. H., Calvert, A., Chen, J., Cho, I., Cotton, M. F., Cutland, C. L., Englund, J. A., Fix, A., Gonik, B., . . . Fries, L. F. (2020). Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1908380

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.